Madrigal Pharmaceuticals, Inc. (MDGL)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Madrigal Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Madrigal Pharmaceuticals, Inc. (MDGL) has returned -10.11% so far this year and 58.04% over the past 12 months. Looking at the last ten years, MDGL has achieved an annualized return of 50.55%, outperforming the S&P 500 Index benchmark, which averaged 12.16% per year.

Based on dividend-adjusted daily data since Feb 6, 2007, MDGL's average daily return is +0.18%, while the average monthly return is +3.81%. At this rate, your investment would double in approximately 1.5 years.

Historically, 47% of months were positive and 53% were negative. The best month was Dec 2022 with a return of +314.0%, while the worst month was Feb 2009 at -84.6%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 8 months.

On a daily basis, MDGL closed higher 48% of trading days. The best single day was Dec 19, 2022 with a return of +268.1%, while the worst single day was Feb 27, 2009 at -78.7%.

Madrigal Pharmaceuticals, Inc. has an annualized alpha of 41.30%, beta of 1.03, and R² of 0.04 versus S&P 500 Index. Calculated based on daily prices since February 07, 2007.

• This stock participated in 125.30% of S&P 500 Index downside but only 103.88% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.04 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

MDGL ranks 77 for risk / return — better than 77% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Madrigal Pharmaceuticals, Inc. (MDGL) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Madrigal Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Madrigal Pharmaceuticals, Inc. was 98.40%, occurring on Feb 11, 2016. Recovery took 2396 trading sessions.

The current Madrigal Pharmaceuticals, Inc. drawdown is 13.16%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Madrigal Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Madrigal Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.